Imfinzi combo misses in NSCLC subpopulation

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Imfinzi durvalumab plus tremelimumab as third-line treatment missed the primary endpoints in non-small cell lung cancer patients with low or negative PD-L1 expression in the Phase III ARCTIC trial.

The trial consisted of two substudies in about 597 patients with locally advanced or metastatic NSCLC who had received at least two prior treatments. Substudy A enrolled patients with high PD-L1 expression, defined as ≥25% of tumor cells with membrane staining, to receive standard of care (SOC) chemotherapy or Imfinzi monotherapy. Substudy B enrolled patients with low or negative PD-L1 expression to receive SOC, Imfinzi monotherapy, tremelimumab monotherapy or Imfinzi plus tremelimumab...